Diagnostics and new treatment regimens for TB: can the Xpert MTB/XDR assay fill the gap for fluoroquinolone testing?

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Observational analysis detected fluoroquinolone resistance in TB isolates, suggesting critical needs for improved diagnostics.

Detection of fluoroquinolone resistance in 4.4% of tested tuberculosis isolates highlights significant gaps in current diagnostics.
Using the Xpert MTB/XDR assay, 319 Mycobacterium tuberculosis strains were analyzed over 14 years, revealing notable resistance patterns.
The assay identified FQ mono-resistance that standard testing missed, emphasizing the importance of rapid drug resistance diagnostics.
Improved testing could enhance treatment options and limit the spread of drug-resistant TB strains in the population.

Armstrong et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark